The global antibody discovery market size is estimated at USD 6.9 billion in 2022 and is expected to reach USD 17.02 billion by 2032, growing at a CAGR of 9.5% during the forecast period.
Antibodies are the proteins produced by the immune system that are capable of binding to specific foreign substances in the body, such as viruses, and destroy them. Antibody discovery is the process of identifying new therapeutic antibodies to treat diseases such as cancers, autoimmune diseases, genetic diseases, HIV, tuberculosis, and other infectious diseases.
The antibody discovery market is driven by several factors, including an increasing number of clinical trials, growing prevalence of chronic diseases, rising healthcare expenditure, health concerns, population size, advancement in research and development activities, rising adoption of advanced technologies, increasing approval of drugs, growing geriatric population, and rising demand for personalized medicine.
Innovative techniques, including phage display and hybridoma technology, are most widely used for antibody discovery. The antibody discovery process plays a crucial role in the development of new vaccines, drugs, and other therapeutic applications by permitting researchers to create certain antibodies that can recognize and target specific antigens.
The market is also rapidly revolutionizing the biotechnology and pharmaceutical industries. It encompasses various advanced technologies to identify and develop antibodies for therapeutic, diagnostic, and research applications. Prominent market players include biotechnology companies, contract research organizations (CROs), and academic institutions, all focusing on creating novel antibodies that target specific diseases. Combined with the surge in disease prevalence, this is expected to fuel the market’s growth during the forecast period.
North America is expected to dominate the market during the forecast period owing to the sophisticated healthcare infrastructure, increasing investment in research and development activities, rise in healthcare investment, growing interest in advanced antibody discovery platforms, rapid adoption of AI-driven antibody drug discovery, and the increasing incidence of chronic diseases such as cancer, HIV, autoimmune disorders, and inflammatory conditions.
The United States holds the largest market share in the region. The growth of the market in the U.S. is driven by the presence of prominent market players, increasing outsourcing in the pharmaceutical industry, advancement in technology, availability of skilled workforce, robust focus on healthcare innovation, increasing awareness programs for early diagnosis, and the rise of personalized medicine which has created the demand for tailored antibody therapies.
Due to the rise in chronic disease prevalence, antibodies are widely used as therapeutics for various diseases. Monoclonal antibodies, in particular, have significant attention in the United States. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 adults have two or more chronic diseases. Therefore, increasing cases of chronic diseases in the country are projected to fuel the antibody discovery market’s expansion in the coming years.
| Report Coverage | Details |
| Market Revenue in 2023 | USD 7.52 Billion |
| Projected Forecast Revenue by 2032 | USD 17.02 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 9.5% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers
An increasing number of cancer case
The rising prevalence of cancer globally has led to the increasing development of research and developments for the rapid detection, diagnosis, and treatment of the disease. As per the European Commission’s estimates published in the European Cancer Information System (ECIS), compared to 2020, new cancer cases rose by 2.3% to reach 2.74 million in 2022. Also, cancer deaths increased by 2.4% compared to 2020.
Antibody engineering offers an informed opinion on the likely evolution of the diagnosis and immunotherapy for developing the treatment of a wide range of diseases, especially cancer therapy. Therefore, with increasing cancer cases, the antibody discovery market is anticipated to grow faster in the coming years.
Increasing adoption of antibody-based therapies
The rapid adoption of antibody-based therapies for various diseases has increased the need for antibodies, which is projected to boost the antibody discovery market. Currently, over 100 monoclonal antibodies are designated as drugs or effective therapeutic agents. Due to their specificity and affinity for various molecular targets, the treatment for various chronic illnesses or diseases uses antibodies, making them indispensable tools in research. They are also the fastest-growing class of biotherapeutics in the market.
Restraint
High cost
The global Antibody Discovery market’s expansion is anticipated to be constrained by the high cost associated with the antibody discovery process. The high cost involved in the research and development of antibodies limits the market growth, which acts as a significant restraint for the market’s growth.
Opportunities
Robust growth of the biopharmaceutical industry
The rapid growth of the biopharmaceutical industry is expected to offer a lucrative opportunity for market growth during the forecast period. The continuous investment in research and development by pharmaceutical and biotechnology companies contributes to the market’s growth. The growth of the biopharmaceutical industry, coupled with the rising number of biologics in development to fight against chronic disorders, also impacts the market positively. In addition, the increasing awareness of personalized medicine and rising focus on developing antibodies tailored to individual patient characteristics has increased the demand for tailored antibody therapies. Thereby driving the market’s growth.
Technological advancements & collaboration
Biopharmaceutical and pharmaceutical companies leveraging advanced technologies to develop more effective and better-targeted drugs. The growth of the antibody discovery market is also driven by technology advancements such as high-throughput screening and artificial intelligence (AI), which help accelerate the antibody discovery processes. In addition, increasing collaborations among key market players is positively influencing the market’s expansion.
Market Segmentation
By Methods
By Antibody Type
By End Users
Buy this Research Report@ https://www.precedenceresearch.com/checkout/3402
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308
